基因组特征作为卵巢癌同源重组缺陷的预测生物标志物
本文综述以肿瘤基因组测序识别突变与染色体变异特征来评估同源重组(HR)缺陷的策略。高级别浆液性卵巢癌中PARP抑制剂(PARPi)的应用体现了该策略的临床相关性;除BRCA1/2有害突变外,HR缺陷还可表现为特定的碱基替换与结构变异特征。基于杂合性丢失(LOH)的指标已用于PARPi试验,但CDK12突变肿瘤并不伴高LOH评分,而表现为串联重复等不同模式,因此需要更复杂的结构变异特征,并需整合多种基因组特征及基因组回复等耐药机制。
要点
- HR缺陷可通过碱基替换与结构染色体变异特征来识别,而不仅依赖BRCA1/2突变。
- 多种量化LOH事件的指标已被提出并用于PARPi临床试验。
- CDK12突变肿瘤不伴高LOH评分,而表现为串联重复等不同基因组改变模式。
核心结论
- DNA修复缺陷是多种癌症的共同特征并日益被视为治疗靶点,筛选患者需对多条冗余DNA修复通路进行功能评估。
- 全基因组测序显示多种突变与染色体改变特征可与特定DNA修复缺陷相关。
- HR缺陷使卵巢癌具有特定的碱基替换与结构染色体变异特征,不仅限于HR相关基因(如BRCA1/2)的有害突变。
- 部分HR缺陷病例(即CDK12突变肿瘤)不伴高LOH评分,而表现为串联重复等不同基因组改变模式。
- 针对DNA修复的靶向治疗,其最佳预测模型最终需整合多种基因组特征,并评估基因组回复等部分或完全再激活DNA修复的耐药机制。
研究设计与样本
- 综述:基于癌症全基因组测序,讨论以突变与染色体改变特征评估DNA修复缺陷(含HR缺陷)的策略。
主要发现
- PARPi用于HR缺陷高级别浆液性卵巢癌,体现了该特征评估策略的临床相关性。
- 多种量化LOH事件的指标已被提出并用于PARPi试验。
- CDK12突变肿瘤不伴高LOH评分,而表现为串联重复等不同基因组改变模式,促使识别并量化更复杂的结构基因组变异特征。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
DNA repair deficiency is a common hallmark of many cancers and is increasingly recognised as a target for cancer therapeutics. Selecting patients for these treatments requires a functional assessment of multiple redundant DNA repair pathways. With the advent of whole-genome sequencing of cancer genomes, it is increasingly recognised that multiple signatures of mutational and chromosomal alterations can be correlated with specific DNA repair defects. The clinical relevance of this approach is underlined by the use of poly-(ADP-ribose) polymerase inhibitors (PARPi) in homologous recombination (HR) deficient high-grade serous ovarian cancers. Beyond deleterious mutations in HR-related genes such as BRCA1/2, it is recognised that HR deficiency endows ovarian cancers with specific signatures of base substitutions and structural chromosomal variation. Multiple metrics quantifying loss-of-heterozygosity (LOH) events were proposed and implemented in trials with PARPi. However, it was shown that some of the HR-deficient cases, i.e. CDK12-mutated tumours, were not associated with high LOH-based scores, but with distinct patterns of genomic alterations such as tandem duplication. Therefore, more complex signatures of structural genomic variation were identified and quantified. Ultimately, optimal prediction models for treatments targeting DNA repair will need to integrate multiples of these genomic signatures and will also need to assess multiple resistance mechanisms such as genomic reversion events that partially or fully re-activate DNA repair.
引用
- Vanderstichele A, Busschaert P, Olbrecht S, et al. Genomic signatures as predictive biomarkers of homologous recombination deficiency in ovarian cancer. Eur J Cancer. 2017. PMID: 28950147. doi:10.1016/j.ejca.2017.08.029
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。